Pharmacologic class: Glycylcycline antibiotic

Therapeutic class: Anti-infective

Pregnancy risk category D


Inhibits protein translation in bacteria by binding to 30S ribosomal subunit and blocking entry of amino-acyl tRNA molecules into ribosomal A site, which in turn prevents incorporation of amino acid residues into elongating peptide chains


Powder for injection (lyophilized): 50 mg/5 ml in single-dose vial

Indications and dosages

Treatment of skin, skin-structure infections, and complicated intra-abdominal infections caused by susceptible organisms

Adults age 18 and older: 100 mg I.V. initially, followed by 50 mg I.V. every 12 hours for 5 to 14 days, depending on infection site and severity and patient's clinical and bacteriologic process

Community-acquired bacterial pneumonia caused by susceptible organisms

Adults age 18 and older: Initially, 100 mg I.V., followed by 50 mg I.V. q 12 hours for 7 to 14 days, depending on infection site and severity and patient's clinical and bacteriologic process

Dosage adjustment

• Severe hepatic impairment


• Hypersensitivity to drug or its components


Use cautiously in:

• mild to moderate hepatic impairment, complicated intra-abdominal infections secondary to perforation, ventilator-associated pneumonia

• pregnant and breastfeeding patients

• children younger than age 18.


• Reconstitute with 5.3 ml of normal saline solution injection or 5% dextrose injection to yield a concentration of 10 mg/ml (50 mg).

• Swirl vial gently until drug dissolves. Immediately withdraw 5 ml of reconstituted solution from vial and add to 100-ml I.V. bag for infusion. Maximum concentration in I.V. bag should be 1 mg/ml.

• Discard reconstituted solution that isn't yellow or orange.

• Administer through dedicated I.V. line or Y-site. If same I.V. line is used for sequential infusion of several drugs, flush before and after infusion, using either normal saline solution injection or 5% dextrose injection. Use infusion solution compatible with tigecycline and other drugs given through same line.

• Administer over 30 to 60 minutes.

• Don't give amphotericin B, chlorpromazine, methylprednisolone, or voriconazole simultaneously through same Y-site.

Adverse reactions

CNS: headache, dizziness, insomnia, asthenia, pseudotumor cerebri

CV: hypertension, hypotension, phlebitis

GI: nausea, vomiting, diarrhea, constipation, abdominal pain, dyspepsia, increased GI enzymes, pseudomembranous colitis, pancreatitis

Hematologic: anemia, leukocytosis, thrombocytopenia

Hepatic: hepatic dysfunction, hepatic failure

Metabolic: antianabolic action (with increased BUN, azotemia, acidosis, and hyperphosphatemia)

Musculoskeletal: back pain

Respiratory: increased cough, dyspnea

Skin: pruritus, rash, sweating, photosensitivity

Other: abscess, fever, infection, pain, peripheral edema, abnormal healing, superinfection, permanent tooth discoloration (during tooth development), increase in all-cause mortality, hypersensitivity reaction (including anaphylaxis)


Drug-drug. Hormonal contraceptives: reduced contraceptive efficacy

Drug-diagnostic tests. Alanine aminotransferase, alkaline phosphatase, amylase, aspartate aminotransferase, bilirubin, blood glucose, blood urea nitrogen: increased

Blood protein, potassium, WBCs: decreased

Patient monitoring

• Monitor prothrombin time or other suitable anticoagulation tests if patient is receiving warfarin concomitantly.

Closely monitor liver function tests; watch for signs and symptoms of hepatic impairment.

Patient teaching

Instruct patient to immediately report rash and other signs or symptoms of allergic reaction.

• Tell patient to complete full course of therapy, even if he feels better.

• Advise patient taking oral hormonal contraceptives to use alternative birth control method during therapy.

• Caution female with childbearing potential to avoid pregnancy because drug may harm fetus.

• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

McGraw-Hill Nurse's Drug Handbook, 7th Ed. Copyright © 2013 by The McGraw-Hill Companies, Inc. All rights reserved


(tye-gi-sye-kleen) ,


(trade name)


Therapeutic: anti infectives
Pharmacologic: glycylcyclines
Pregnancy Category: D


Complicated skin/skin structure infections, complicated intra-abdominal infections, or community-acquired bacterial pneumonia caused by susceptible bacteria (Should only be used when alternative treatments are not suitable; should NOT be used for diabetic foot infections).


Inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit.

Therapeutic effects

Resolution of infection.
Active against the following Gram-positive bacteria: Enterococcus faecalis(vancomycin-susceptible strains only), Staphylococcus aureus (methicillin-sensitive and methicillin-resistant strains), Streptococcus agalactiae, Streptococcus anginosus, Streptococcus pneumoniae, and Streptococcus pyogenes.Also active against these Gram-positive organisms: Citrobacter freundii, Enterobacter cloacae, Escherichia coli, Haemophilus influenzae (beta-lactamase negative strains only), Legionella pneumophila, Klebsiella oxytoca, and Klebsiella pneumoniae.Additionally active against the following anaerobes: Bacteroides fragilis, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides vulgatus, Clostridium perfringens, and Peptostreptococcus micros.


Absorption: IV administration results in complete bioavailability.
Distribution: Widely distributed with good penetration into gall bladder, lung, and colon; crosses the placenta.
Metabolism and Excretion: Minimal metabolism; primary route of elimination is biliary/fecal excretion of unchanged drug and metabolites (59%), 33% renal (22% unchanged).
Half-life: 27.1 hr (after 1 dose); 42.4 hr after multiple doses.

Time/action profile (blood levels)

IVrapidend of infusion12 hr


Contraindicated in: Hypersensitivity;Diabetic foot infectionsHospital-acquired or ventilator-associated pneumonia Pediatric: Children.
Use Cautiously in: Complicated intra-abdominal infections due to perforation;Severe hepatic impairment (↓ maintenance dose recommended); Geriatric: May be more sensitive to adverse effects; Obstetric / Lactation: Use in pregnancy only when potential maternal benefit outweighs fetal risk; use cautiously during lactation.

Adverse Reactions/Side Effects

Central nervous system

  • somnolence


  • stevens-johnson syndrome (life-threatening)


  • pancreatitis (life-threatening)
  • pseudomembranous colitis (life-threatening)
  • nausea (most frequent)
  • vomiting (most frequent)
  • altered taste
  • anorexia
  • dry mouth
  • hepatotoxicity
  • jaundice


  • ↑ serum creatinine


  • hyperglycemia
  • hypoglycemia

Fluid and Electrolyte

  • hypocalcemia
  • hyponatremia


  • pneumonia


  • injection site reactions


  • death (life-threatening)
  • allergic reactions


Drug-Drug interaction

May ↓ the effectiveness of hormonal contraceptives.Effects on warfarin are unknown (monitoring recommended).


Intravenous (Adults >18 yr) 100 mg initially, then 50 mg every 12 hr for 5–14 days (skin/skin structure infections and intra-abdominal infections) or 7–14 days (pneumonia).

Hepatic Impairment

Intravenous (Adults >18 yr) Child-Pugh C—100 mg initially, then 25 mg every 12 hr.


Lyophilized powder for reconstitution: 50 mg/vial

Nursing implications

Nursing assessment

  • Assess for infection (vital signs; appearance of wound, sputum, urine, and stool; WBC) at beginning of and throughout therapy.
  • Obtain specimens for culture and sensitivity before initiating therapy. 1st dose may be given before receiving results.
  • Before initiating therapy, obtain a history of tetracycline hypersensitivity; may also have an allergic response to tigecycline.
  • Monitor bowel function. Diarrhea, abdominal cramping, fever, and bloody stools should be reported to health care professional promptly as a sign of pseudomembranous colitis. May begin up to several weeks following cessation of therapy.
  • Assess patient for signs of pancreatitis (nausea, vomiting, abdominal pain, increased serum lipase or amylase) periodically during therapy. May require discontinuation of therapy.
  • Assess for rash periodically during therapy. May cause Stevens-Johnson syndrome. Discontinue therapy if severe or if accompanied with fever, general malaise, fatigue, muscle or joint aches, blisters, oral lesions, conjunctivitis, hepatitis and/or eosinophilia.
  • Lab Test Considerations: May cause anemia, leukocytosis, and thrombocythemia.
    • May cause ↑ serum alkaline phosphatase, amylase, bilirubin, LDH, AST, and ALT.
    • May cause hyperglycemia, hypokalemia, hypoproteinemia, hypocalcemia, hyponatremia, and ↑ BUN level.

Potential Nursing Diagnoses

Risk for infection (Indications)


  • May cause yellow-brown discoloration and softening of teeth and bones if administered prenatally or during early childhood. Not recommended for children under 8 yr of age or during pregnancy or lactation unless used for the treatment of anthrax.
  • Intravenous Administration
  • Intermittent Infusion: Reconstitute each vial with 5.3 mL of 0.9% NaCl or D5W to achieve a concentration of 10 mg/mL. Diluent: Dilute further in 100 mL of D5W, LR, or 0.9% NaCl. Reconstituted solution should be yellow to orange in color. Do not administer solutions that are discolored or contain particulate matter. Infusion is stable for up to 24 hr at room temperature or for up to 48 hr if refrigerated.Concentration: Final concentration of infusion should be ≤1 mg/mL.
  • Rate: Infuse over 30–60 min. Flush line before and after infusion with 0.9% NaCl or D5W.
  • Y-Site Compatibility: acyclovir, alfentanil, allopurinol, amifostine, amikacin, aminocaproic acid, aminophylline, amphotericin B liposome, ampicillin, ampicillin/sulbactam, argatroban, azithromycin, aztreonam, bivalirudin, bumetanide, buprenorphine, busulfan, butorphanol, calcium chloride, calcium gluconate, carboplatin, carmustine, caspofungin, cefazolin, cefepime, cefotaxime, cefotetan, cefoxitin, ceftazidime, ceftriaxone, cefuroxime, ciprofloxacin, cisatracurium, cisplatin, clindamycin, cyclophosphamide, cyclosporine, cytarabine, dacarbazine, dactinomycin, daptomycin, daunorubicin hydrochloride, dexamethasone, dexmedetomidine, dexrazoxane, digoxin, diltiazem, diphenhydramine, dobutamine, docetaxel, dolasetron, dopamine, doripenem, doxorubicin hydrochloride, doxorubicin liposome, droperidol, enalaprilat, epinephrine, eptifibatide, ertapenem, erythromycin, esmolol, etoposide, etoposide phosphate, famotidine, fenoldopam, fentanyl, fluconazole, fludarabine, fluorouracil, foscarnet, fosphenytoin, furosemide, ganciclovir, gemcitabine, gentamicin, glycopyrrolate, granisetron, haloperidol, heparin, hydrocortisone, hydromorphone, ifosfamide, imipenem/cilastatin, insulin, irinotecan, isoproterenol, ketorolac, labetalol, lansoprazole, leucovorin, levofloxacin, lidocaine, linezolid, lorazepam, magnesium sulfate, mannitol, mechlorethamine, melphalan, meperidine, meropenem, mesna, methohexital, methotrexate, methyldopate, metoclopramide, metoprolol, metronidazole, midazolam, milrinone, mitomycin, mitoxantrone, morphine, moxifloxacin, mycophenolate, nafcillin, nalbuphine, naloxone, nesiritide, nitroglycerin, nitroprusside, norepinephrine, octreotide, ondansetron, oxaliplatin, oxytocin, paclitaxel, palonosetron, pamidronate, pancuronium, pantoprazole, pemetrexed, pemtamidine, pentazocine, pentobarbital, phenobarbital, phenylephrine, piperacillin/tazobactam, potassium acetate, potassium chloride, potassium phosphates, procainamide, prochlorperazine, promethazine, propofol, propranolol, ranitidine, remifentanil, rocuronium, sodium acetate, sodium bicarbonate, sodium phosphates, streptozocin, succinylcholine, sufentanil, tacrolimus, telavancin, tenioposide, theophylline, thiopental, thiotepa, ticarcillin/clavulanate, tirofiban, tobramycin, topotecan, trimethoprim/sulfamethoxazole, vancomycin, vasopressin, vecuronium, vinblastine, vincristine, vinorelbine, zidovudine, zoledronic acid
  • Y-Site Incompatibility: amiodarone, amphotericin B colloidal, amphotericin B lipid complex, bleomycin, chloramphenicol, chlorpromazine, dantrolene, diazepam, epirubicin, esomeprazole, hydralazine, idarubicin, nicardipine, phenytoin, quinupristin/dalfopristin, verapamil

Patient/Family Teaching

  • Advise patient that full course of therapy should be completed, even if feeling better. Skipping doses or not completing full course of therapy may result in decreased effectiveness and increased risk of bacterial resistance.
  • Instruct patient to notify health care professional if fever and diarrhea develop, especially if stool contains blood, pus, or mucus. Advise patient not to treat diarrhea without consulting health care professional.
  • Advise patient to report the signs of superinfection (black, furry overgrowth on the tongue, vaginal itching or discharge, loose or foul-smelling stools). Skin rash, pruritus, and urticaria should also be reported.
  • Advise female patient to use a nonhormonal method of contraception while taking tigecycline and until next menstrual period.

Evaluation/Desired Outcomes

  • Resolution of signs and symptoms of infection.
Drug Guide, © 2015 Farlex and Partners
Mentioned in ?
References in periodicals archive ?
FDA drug safety communication: FDA warns of increased risk of death with IV antibacterial Tygacil (tigecycline) and approves new boxed warning 2017.
He has worked on numerous antibacterial programs including the development of the marketed antibiotics; Suprax, Zosyn and Tygacil.
Group 1 received 1 mg/mL of tigecycline (Tygacil, PFIZER) topically.
The clear areas in the right half of the left-hand plate show that the Klebsiella with NDM 1 was sensitive to the antibiotic tigecycline (manufactured by Pfizer under the trade name Tygacil) By Ben Hirschler/London Thirty years ago, when the world faced the terrifying prospect of an untreatable disease known as Aids, big drugmakers scented an opportunity and raced to develop new medicines.
Bacteria that contain NDM-1 are resistant to antibiotics currently available, with the exception of tigecycline (Tygacil) and colistin (Colomycin), according to an article in the September 2010 issue of The Lancet.
In a pooled analysis of 13 clinical trials of patients with different types of infections, treatment with tigecycline (Tygacil) was associated with increased mortality when compared with other antibiotics, according to the statement.
(18.) United States Food and Drug Administration (FDA), Highlights of prescribing information Tygacil. http://www.fda.gov/Safety/MedWatch/ SafetyInformation/SafetyRelatedDrugLabelingChanges/ucm132714.htm (accessed 6 April 2010).
Tygacil (tigecycline) for injection [Package insert].
The LR-MRSA was susceptible to vancomycin, daptomycin (Cubicin), and tigecycline (Tygacil), which were used to treat these patients.